General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0BAWRQ
ADC Name
CN116916962A-ADC-B2
Synonyms
ADC-B2
   Click to Show/Hide
Organization
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Drug Status
Investigative
Drug-to-Antibody Ratio
4.3
Structure
Antibody Name
hIgG4
 Antibody Info 
Antigen Name
C-C chemokine receptor type 2 (CCR2)
 Antigen Info 
Payload Name
Compound No.14
 Payload Info 
Linker Name
Mc-Val-Ala-PABC
 Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
C-21
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
2.63
nM
CVCL_0006
Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 2.63 nM High hCCR2 expression (hCCR2+++)
Method Description
THP 1, 15,000cells/254uL per welld were plated at set in 384 well flat plate, in the appropriate growth media. The cell plates were dosed with 5uL of the hCCR2 targeting-ADC samples and then incubated at 37°C for 20 hours. At the end of the incubation 10uL/well of the QUANTJ-LucTM (InvivoGenftrep-qlc1) were added and luminescence was measured immediately using the LeadSeeker.

   Click to Show/Hide
In Vitro Model Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia THP1 cells CVCL_0006
References
Ref 1 Antibody-drug conjugates